

Clinical trials of sitagliptin

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------------|
| sitagliptin vs | | | |
| Stafford , 2011 [NCT00451113] n=NA follow-up: | - | older adults with type 2 diabetes mellitus | |
| sitagliptin vs control (add on MET) | | | |
| Reasner , 2011 [NCT00482729]) n=NA follow-up: | sitagliptin/metformin 50/500 mg bid uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid versus metformin monotherapy | drug-naive patients with type 2 diabetes | Cross over NA |
| sitagliptin vs glimepiride (add on MET) | | | |
| Arechavaleta , 2011 [NCT00701090] n=516/519 follow-up: 30 weeks | sitagliptin 100 mg daily versus glimepiride (starting dose 1 mg/day and up-titrated, based upon patient's self-monitoring of blood glucose results, to a maximum dose of up to 6 mg/day) | patients with type 2 diabetes inadequately controlled on metformin monotherapy | Parallel groups double-blind |
| sitagliptin monotherapy vs metformin | | | |
| Aschner , 2010 [NCT00449930] n=528/522 follow-up: 24 weeks | once-daily sitagliptin 100 mg versus twice-daily metformin 1000 mg | treatment-naive patients with type 2 diabetes | double-blind |
| sitagliptin+pio vs metformin+pio | | | |
| Derosa , 2010 n=NA follow-up: | pioglitazone 30 mg plus sitagliptin 100 mg once a day versus pioglitazone 15 mg plus metformin 850 mg twice a day | poorly controlled type 2 diabetes mellitus patients | |
| sitagliptin vs placebo | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|---|
| Goldstein , 2007 [NCT00103857] n=NA follow-up: | sitagliptin 100 mg daily versus placebo | - | |
| Hanefeld , 2007 n=NA follow-up: | sitagliptin 25 mg or 50 mg or 100 mg daily versus placebo | - | |
| TECOS , 2015 [NCT00790205] n=7332/7339 follow-up: 3.0 years (median) | sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily versus placebo | patients with Type 2 Diabetes Mellitus having a history of cardiovascular disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0% | Parallel groups double-blind 38 countries |
| sitagliptin 50mg bid monotherapy vs placebo | | | |
| Scott* (sit vs pbo) , 2007 n=NA follow-up: | sitagliptin 50 mg b.i.d versus placebo | - | |
| sitagliptin monotherapy vs placebo | | | |
| Aschner , 2006 [NCT00087516] n=NA follow-up: 24 weeks | sitagliptin 100 or 200 mg daily versus placebo | patients with type 2 diabetes | |
| Barzilai , 2011 [NCT00305604] n=NA follow-up: 24 weeks | once-daily sitagliptin (100 or 50 mg, depending on renal function) versus placebo | elderly patients with type 2 diabetes | double-blind US |
| Chan , 2008 n=65/26 follow-up: 12 weeks | sitagliptin versus placebo | patients with type 2 diabetes and chronic renal insufficiency | double-blind |
| Mohan , 2009 n=NA follow-up: 18 weeks | sitagliptin 100mg once daily monotherapy versus placebo | Chinese, Indian, and Korean patients with type 2 diabetes inadequately controlled by diet and exercise. | double-blind |
| Nonaka , 2008 [NCT00371007] n=NA follow-up: | sitagliptin 100 mg daily monotherapy versus placebo | Japanese patients with type 2 diabetes | double-blind |
| Raz , 2006 n=NA follow-up: | sitagliptin 100 mg (or 200 mg) daily versus placebo | patients with type 2 diabetes mellitus and inadequate glycaemic control | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|----------------------------------|
| sitagliptin vs placebo (add on insulin+/-MET) | | | |
| Vilsbll , 2010 [NCT00395343] n=322/319 follow-up: | once-daily sitagliptin 100 mg versus placebo | patients with type 2 diabetes inadequately controlled on long-acting, intermediate-acting or premixed insulin | double-blind |
| sitagliptin vs placebo (add on MET) | | | |
| Charbonnel , 2006 [NCT0086515] n=NA follow-up: | sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy); | - | |
| Nauck , 2007 [NCT00094770] n=NA follow-up: | sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy); | - | |
| raz , 2008 [NCT00337610] n=NA follow-up: | sitagliptin 100 mg once daily versus placebo | patients with type 2 diabetes | |
| Scott** (sit vs pbo on top met) , 2007 n=NA follow-up: | sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy). | patients with type 2 diabetes who were inadequately on MET monotherapy | |
| sitagliptin vs placebo (add on PIO) | | | |
| Rosenstock , 2006 [NCT00086502] n=NA follow-up: 24 weeks | sitagliptin 100 mg once daily versus placebo | patients with type 2 diabetes and inadequate glycemic control | double-blind |
| sitagliptin vs placebo (on top PIO) | | | |
| Rosenstock (sit on top pio vs pbo) , 2006 [NCT00086502] n=NA follow-up: | sitagliptin 100 mg daily (add-on to pioglitazone therapy) versus placebo (add-on to pioglitazone therapy); | - | |
| sitagliptin vs placebo (on-top glimepiride+/- metformine) | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|----------------------------------|
| Hermansen , 2007 n=NA follow-up: | sitagliptin 100 mg daily (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin)ocumen versus placebo (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin); | - | |
| sitagliptin vs rosiglitazone (add on MET) | | | |
| Rigby , 2010 n=NA follow-up: 16 weeks | sitagliptin phosphate, 100 mg daily versus rosiglitazone maleate, 4 mg daily | type 2 diabetes mellitus inadequately controlled by metformin monotherapy | open |
| sitagliptin vs Sulphonylurea (on top MET) | | | |
| Al Sifri , 2011 n=507/514 follow-up: | sitagliptin 100 mg qd versus prestudy sulphonylurea | Muslim patients with type 2 diabetes who were treated with a stable dose of a sulphonylurea with or without metformin for at least 3 months | Parallel groups open |
| sitagliptin monotherapy vs voglibose | | | |
| Iwamoto , 2010 n=NA follow-up: 12 weeks | sitagliptin 50 mg once daily monotherapy versus voglibose 0.2 mg thrice daily before meals | Japanese patients with type 2 diabetes | double-blind |
| sitagliptin 50mg bid monotherapy vs glipizide | | | |
| Scott* (sit vs glipi) , 2007 n=NA follow-up: 12 weeks | sitagliptin 50mg bid versus glipizide 5mg to 20 mg dailyitm | patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise | double-blind |
| sitagliptin vs metformin | | | |
| Goldstein (sit vs met) , 2007 n=NA follow-up: | sitagliptin 100 dailyily versus metformin 1000 mg or 2000 mg daily;imag | - | |
| Goldstein (sit+met vs met) , 2007 n=NA follow-up: | sitagliptin 50 mg daily plus metformin 1000 or 2000 mg daily4 <i>versus</i> <i>metformin1000or2000mgdaily</i> | - | |
| sitagliptin vs pioglitazone | | | |
| Prez-Monteverde , 2011 [NCT00541450] n=NA follow-up: 12 weeks | sitagliptin100 mg qd versus pioglitazone 15 mg qd, up-titrated to 30 mg after 6 weeks | drug-naive patients with type 2 diabetes | double-blind |

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

References

Stafford , 2011:

Stafford S, Elahi D, Meneilly GS Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc 2011;59:1148-9 [21668924] [10.1111/j.1532-5415.2011.03438.x](https://doi.org/10.1111/j.1532-5415.2011.03438.x)

Reasner, 2011:

Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:644-52 [21410627] [10.1111/j.1463-1326.2011.01390.x](https://doi.org/10.1111/j.1463-1326.2011.01390.x)

Arechavaleta, 2011:

Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-8 [21199268] [10.1111/j.1463-1326.2010.01334.x](https://doi.org/10.1111/j.1463-1326.2010.01334.x)

Aschner, 2010:

Aschner P, Katzefff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-61 [20070351] [10.1111/j.1463-1326.2009.01187.x](https://doi.org/10.1111/j.1463-1326.2009.01187.x)

Derosa , 2010:

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95 [20015525] [10.1016/j.metabol.2009.10.007](https://doi.org/10.1016/j.metabol.2009.10.007)

Goldstein, 2007:

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007;30:1979-87 [17485570] 10.2337/dc07-0627

Hanefeld, 2007:

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. *Curr Med Res Opin* 2007;23:1329-39 [17559733] 10.1185/030079907X188152

TECOS, 2015:

Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. *Am Heart J* 2013;166:983-989.e7 [24268212]

Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Obes Metab* 2015;17:395-402 [25600421]

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2015 Jul 16;373:232-42 [26052984] 10.1056/NEJMoa1501352

Scott* (sit vs pbo), 2007:

Scott R, Wu M, Sanchez M, Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. *Int J Clin Pract* 2007;61:171-80 [17156104] 10.1111/j.1742-1241.2006.01246.x

Aschner, 2006:

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2006;29:2632-7 [17130196] 10.2337/dc06-0703

Barzilai, 2011:

Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Curr Med Res Opin* 2011;27:1049-58 [21428727] 10.1185/03007995.2011.568059

Chan, 2008:

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 2008;10:545-55 [18518892] 10.1111/j.1463-1326.2008.00914.x

Mohan , 2009:

Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. *Diabetes Res Clin Pract* 2009;83:106-16 [19097665] 10.1016/j.diabres.2008.10.009

Nonaka, 2008:

Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;79:291-8 [17933414] 10.1016/j.diabres.2007.08.021

Raz, 2006:

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* 2006;49:2564-71 [17001471] 10.1007/s00125-006-0416-z

Vilsbll, 2010:

Vilsbll T, Rosenstock J, Yki-Jrvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12:167-77 [20092585] [10.1111/j.1463-1326.2009.01173.x](https://doi.org/10.1111/j.1463-1326.2009.01173.x)

Charbonnel, 2006:

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 2006;29:2638-43 [17130197] [10.2337/dc06-0706](https://doi.org/10.2337/dc06-0706)

Nauck, 2007:

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab* 2007;9:194-205 [17300595] [10.1111/j.1463-1326.2006.00704.x](https://doi.org/10.1111/j.1463-1326.2006.00704.x)

Seck TL, Engel SS, Williams-Herman DE, Sisk CM, Golm GT, Wang H, Kaufman KD, Goldstein BJ Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. *Diabetes Res Clin Pract* 2011;93:e15-7 [21477878] [10.1016/j.diabres.2011.03.006](https://doi.org/10.1016/j.diabres.2011.03.006)

Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. *Int J Clin Pract* 2010;64:562-76 [20456211] [10.1111/j.1742-1241.2010.02353.x](https://doi.org/10.1111/j.1742-1241.2010.02353.x)

raz, 2008:

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr Med Res Opin* 2008;24:537-50 [18194595] [10.1185/030079908X260925](https://doi.org/10.1185/030079908X260925)

Scott (sit vs pbo on top met), 2007:**

Scott R, Loeys T, Davies MJ, Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10:959-69 [18201203] [10.1111/j.1463-1326.2007.00839.x](https://doi.org/10.1111/j.1463-1326.2007.00839.x)

Rosenstock , 2006:

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 2006;28:1556-68 [17157112] [10.1016/j.clinthera.2006.10.007](https://doi.org/10.1016/j.clinthera.2006.10.007)

Rosenstock (sit on top pio vs pbo), 2006:

Ristic S, Byiers S, Foley J, Holmes D Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab* 2005;7:692-8 [16219012] [10.1111/j.1463-1326.2005.00539.x](https://doi.org/10.1111/j.1463-1326.2005.00539.x)

Hermansen, 2007:

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab* 2007;9:733-45 [17593236] [10.1111/j.1463-1326.2007.00744.x](https://doi.org/10.1111/j.1463-1326.2007.00744.x)

Rigby , 2010:

Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. *Endocr Pract* 2010;16:53-63 [19789153] [10.4158/EP09146.OR](https://doi.org/10.4158/EP09146.OR)

Al Sifri, 2011:

Al Sifri S, Basiouny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea

during Ramadan: a randomised trial. Int J Clin Pract 2011;65:1132-40 [21951832] [10.1111/j.1742-1241.2011.02797.x](#)

Iwamoto , 2010:

Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12:613-22 [20590736] [10.1111/j.1463-1326.2010.01197.x](#)

Scott* (sit vs glipi), 2007:

Scott R, Wu M, Sanchez M, Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80 [17156104] [10.1111/j.1742-1241.2006.01246.x](#)

Goldstein (sit vs met), 2007:

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87 [17485570] [10.2337/dc07-0627](#)

Goldstein (sit+met vs met), 2007:

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87 [17485570] [10.2337/dc07-0627](#)

Prez-Monteverde, 2011:

Prez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract 2011;65:930-8 [21849007] [10.1111/j.1742-1241.2011.02749.x](#)

∞

Entry terms: sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431,